FDA Inspection
U.S. Continental Marketing, Inc.U.S. Continental Marketing, Inc. – FDA Inspection, Jul 21, 2022
Record Details
This FDA Inspection record concerns U.S. Continental Marketing, Inc., with an inspection on July 21, 2022, issued by the Center for Drug Evaluation and Research, covering drugs.
- Inspection Date
- July 21, 2022
- Product Type
- Drugs
View Company Profile
ID · 76d0784f-cad7-4f1a-8eb4-6b7b23f7b05e
Inspection Facts
Official Action Indicated (OAI)
Significant objectionable conditions were found and regulatory or administrative action is recommended.
- Inspection number
- 1175769
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
FDA Citations
5- 21 CFR 211.25(a)Training--operations, GMPs, written procedures
- 21 CFR 211.63Equipment Design, Size and Location
- 21 CFR 211.125(a)Strict control not exercised over labeling issued
- 21 CFR 211.22(d)Procedures not in writing, fully followed
- 21 CFR 211.67(b)Written procedures not established/followed
Full citation text and observation details available on the Dashboard.
Other FDA inspections of U.S. Continental Marketing, Inc.
1| Date | Classification | Office | Project area |
|---|---|---|---|
| October 30, 2018 | OAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for U.S. Continental Marketing, Inc.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.